Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) CEO John M. Evans sold 30,000 shares of the company's stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $65.75, for a total value of $1,972,500.00. Following the completion of the transaction, the chief executive officer now owns 1,088,520 shares of the company's stock, valued at approximately $71,570,190. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Beam Therapeutics Trading Down 4.1 %

Beam Therapeutics stock opened at $62.98 on Monday. The stock has a market cap of $4.43 billion, a P/E ratio of -17.45 and a beta of 1.39. The stock has a 50 day moving average of $44.93 and a 200-day moving average of $52.03. Beam Therapeutics Inc. has a 52 week low of $27.77 and a 52 week high of $116.91.

Beam Therapeutics (NASDAQ:BEAM – Get Rating) last announced its quarterly earnings data on Monday, May 9th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.09. Beam Therapeutics had a negative return on equity of 28.02% and a negative net margin of 395.37%. The firm had revenue of $8.40 million for the quarter, compared to analysts' expectations of $44.15 million. During the same period last year, the business posted ($3.35) earnings per share. The firm's revenue for the quarter was up 139900.0% on a year-over-year basis. As a group, equities analysts predict that Beam Therapeutics Inc. will post -4.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Beam Therapeutics

Analysts Set New Price Targets

A number of research firms have weighed in on BEAM. BMO Capital Markets upped their price target on Beam Therapeutics from $41.00 to $61.00 in a report on Monday, July 18th. Credit Suisse Group began coverage on Beam Therapeutics in a report on Thursday, April 28th. They issued a "neutral" rating and a $62.00 price target for the company. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Beam Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $113.71.

Beam Therapeutics Company Profile

(Get Rating)

Beam Therapeutics Inc, a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia.

Recommended Stories

• Get a free copy of the StockNews.com research report on Beam Therapeutics (BEAM)
• Use These To Find Your Stock's Support and Resistance Levels
• Is Boeing Stock is Ready for Lift-Off ?
• Elon Musk is Out, But Should You Be In Twitter Stock?
• 3 Earnings Announcements That Could Surprise
• Twitter's Up For Third Week In A Row: What's Next For The Stock?

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.